Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors

It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatocellular carcinoma 2021-01, Vol.8, p.263-270
Main Authors: Chen, Li, Liu, Zhi-Xing, Bi, Qiu-Chen, Zhao, Jun, Liang, Qing-Rong, Tang, Qun
Format: Article
Language:English
Subjects:
Abdomen
Ablation
Apoptosis
Biopsy
Cancer therapies
Cell division
Cell proliferation
Chemotherapy
combined therapy
Correlation analysis
Cytotoxicity
Dehydration
Drug dosages
Ethanol
Iodine
Kruskal-Wallis test
Laboratory animals
Liver cancer
Necrosis
new indication
Original Research
Paclitaxel
Peat
percutaneous ethanol ablation therapy
Rabbits
Scanners
Sectioning
Tumors
Ultrasonic imaging
Ultrasound
vx2 liver cancer model
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73
cites cdi_FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73
container_end_page 270
container_issue
container_start_page 263
container_title Journal of hepatocellular carcinoma
container_volume 8
creator Chen, Li
Liu, Zhi-Xing
Bi, Qiu-Chen
Zhao, Jun
Liang, Qing-Rong
Tang, Qun
description It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy (PEPCT) of VX2 carcinoma, a rabbit liver cancer model. A six-arm study was designed to quantify the correlation between paclitaxel (PTX) dose and tumor necrosis or cell proliferation, including sham group (2 mL saline, n=6), incremented dose of PTX (0, 12.5, 25, 37.5 mg) in 2.0 mL ethanol (n=6) and a conventional PEAT group (n=6) as comparison. The test was followed by contrast-enhanced ultrasonic (CEUS) before 7-day sacrifice, tumor harvest, and sectioning. Tumor necrosis ratio was radiologically and histologically quantified; modified proliferation index ( -PI) was proposed to quantify the PTX's pharmacological effects. A linear regression model was set to correlate the PTX dose with tumor necrosis ratio or cell proliferation index. The difference of radiological, histological necrosis ratio (HNR) and modified PI in six groups was analyzed via Kruskal-Wallis -test, Welch analysis of variance and one-way ANOVA. Incremental increases of PTX (0, 12.5, 25, 37.5 mg) correlated with greater fraction of tumor necrosis (R = 0.946, P
doi_str_mv 10.2147/JHC.S301083
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8b0d1e685de745b79e5e764fe8b4497f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8b0d1e685de745b79e5e764fe8b4497f</doaj_id><sourcerecordid>2528067943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73</originalsourceid><addsrcrecordid>eNpdks9rFDEYhgdRbKk9eZcBL4JMTSbJJLkIstS2smDRrXgyJJMv3SyZyZrMFPvfN3XX0nrKr4eHlzdfVb3G6KTFlH_4cr44-U4QRoI8qw7blpGGyU4-f7Q_qI5z3iCEcDkhLl5WB4RIxDvZHVa_rsKUdI7zaJuz2Vuw9SWkfp70CHHO9em01mMMzaXug5_0Hwj1Ig7GjwVcrSHp7W3tYqq_aWP8VP_42dZLfwOpXs1DTPlV9cLpkOF4vx5VV59PV4vzZvn17GLxadn0FLGpEQwxKqzEhFhmHUWOSsMwSES5M4YLQQgmumPYagRSQkFazDEntNUOODmqLnZeG_VGbZMfdLpVUXv19yKma6XT5PsAShhkMXSCWeCUGS6BAe-oA2EoldwV18edazubAWwPY2koPJE-fRn9Wl3HGyVQsaKuCN7tBSn-niFPavC5hxB2naqWYUlKekIL-vY_dBPnNJaqCtUWIZeUFOr9jupTzDmBewiDkbofA1XGQO3HoNBvHud_YP99OrkD16msUw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528067943</pqid></control><display><type>article</type><title>Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors</title><source>Publicly Available Content Database</source><source>Taylor &amp; Francis Open Access Journals</source><source>PubMed Central</source><creator>Chen, Li ; Liu, Zhi-Xing ; Bi, Qiu-Chen ; Zhao, Jun ; Liang, Qing-Rong ; Tang, Qun</creator><creatorcontrib>Chen, Li ; Liu, Zhi-Xing ; Bi, Qiu-Chen ; Zhao, Jun ; Liang, Qing-Rong ; Tang, Qun</creatorcontrib><description>It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy (PEPCT) of VX2 carcinoma, a rabbit liver cancer model. A six-arm study was designed to quantify the correlation between paclitaxel (PTX) dose and tumor necrosis or cell proliferation, including sham group (2 mL saline, n=6), incremented dose of PTX (0, 12.5, 25, 37.5 mg) in 2.0 mL ethanol (n=6) and a conventional PEAT group (n=6) as comparison. The test was followed by contrast-enhanced ultrasonic (CEUS) before 7-day sacrifice, tumor harvest, and sectioning. Tumor necrosis ratio was radiologically and histologically quantified; modified proliferation index ( -PI) was proposed to quantify the PTX's pharmacological effects. A linear regression model was set to correlate the PTX dose with tumor necrosis ratio or cell proliferation index. The difference of radiological, histological necrosis ratio (HNR) and modified PI in six groups was analyzed via Kruskal-Wallis -test, Welch analysis of variance and one-way ANOVA. Incremental increases of PTX (0, 12.5, 25, 37.5 mg) correlated with greater fraction of tumor necrosis (R = 0.946, P&lt;0.001 for radiological necrosis ratio [RNR], R = 0.843, P&lt;0.001 forHNR), indicating that one week after procedure PTX's anti-proliferation and ethanol's dehydration co-induced severe tumor necrosis. Correlation analysis further testified a significant association between PTX dose and -PI (R = 0.860, P&lt;0.001). These results suggest a clear role for PTX-induced cytotoxicity and support the use of chemotherapeutic drugs in ablation therapy.</description><identifier>ISSN: 2253-5969</identifier><identifier>EISSN: 2253-5969</identifier><identifier>DOI: 10.2147/JHC.S301083</identifier><identifier>PMID: 33907696</identifier><language>eng</language><publisher>New Zealand: Taylor &amp; Francis Ltd</publisher><subject>Abdomen ; Ablation ; Apoptosis ; Biopsy ; Cancer therapies ; Cell division ; Cell proliferation ; Chemotherapy ; combined therapy ; Correlation analysis ; Cytotoxicity ; Dehydration ; Drug dosages ; Ethanol ; Iodine ; Kruskal-Wallis test ; Laboratory animals ; Liver cancer ; Necrosis ; new indication ; Original Research ; Paclitaxel ; Peat ; percutaneous ethanol ablation therapy ; Rabbits ; Scanners ; Sectioning ; Tumors ; Ultrasonic imaging ; Ultrasound ; vx2 liver cancer model</subject><ispartof>Journal of hepatocellular carcinoma, 2021-01, Vol.8, p.263-270</ispartof><rights>2021 Chen et al.</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Chen et al. 2021 Chen et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73</citedby><cites>FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2528067943/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2528067943?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33907696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Li</creatorcontrib><creatorcontrib>Liu, Zhi-Xing</creatorcontrib><creatorcontrib>Bi, Qiu-Chen</creatorcontrib><creatorcontrib>Zhao, Jun</creatorcontrib><creatorcontrib>Liang, Qing-Rong</creatorcontrib><creatorcontrib>Tang, Qun</creatorcontrib><title>Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors</title><title>Journal of hepatocellular carcinoma</title><addtitle>J Hepatocell Carcinoma</addtitle><description>It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy (PEPCT) of VX2 carcinoma, a rabbit liver cancer model. A six-arm study was designed to quantify the correlation between paclitaxel (PTX) dose and tumor necrosis or cell proliferation, including sham group (2 mL saline, n=6), incremented dose of PTX (0, 12.5, 25, 37.5 mg) in 2.0 mL ethanol (n=6) and a conventional PEAT group (n=6) as comparison. The test was followed by contrast-enhanced ultrasonic (CEUS) before 7-day sacrifice, tumor harvest, and sectioning. Tumor necrosis ratio was radiologically and histologically quantified; modified proliferation index ( -PI) was proposed to quantify the PTX's pharmacological effects. A linear regression model was set to correlate the PTX dose with tumor necrosis ratio or cell proliferation index. The difference of radiological, histological necrosis ratio (HNR) and modified PI in six groups was analyzed via Kruskal-Wallis -test, Welch analysis of variance and one-way ANOVA. Incremental increases of PTX (0, 12.5, 25, 37.5 mg) correlated with greater fraction of tumor necrosis (R = 0.946, P&lt;0.001 for radiological necrosis ratio [RNR], R = 0.843, P&lt;0.001 forHNR), indicating that one week after procedure PTX's anti-proliferation and ethanol's dehydration co-induced severe tumor necrosis. Correlation analysis further testified a significant association between PTX dose and -PI (R = 0.860, P&lt;0.001). These results suggest a clear role for PTX-induced cytotoxicity and support the use of chemotherapeutic drugs in ablation therapy.</description><subject>Abdomen</subject><subject>Ablation</subject><subject>Apoptosis</subject><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Cell division</subject><subject>Cell proliferation</subject><subject>Chemotherapy</subject><subject>combined therapy</subject><subject>Correlation analysis</subject><subject>Cytotoxicity</subject><subject>Dehydration</subject><subject>Drug dosages</subject><subject>Ethanol</subject><subject>Iodine</subject><subject>Kruskal-Wallis test</subject><subject>Laboratory animals</subject><subject>Liver cancer</subject><subject>Necrosis</subject><subject>new indication</subject><subject>Original Research</subject><subject>Paclitaxel</subject><subject>Peat</subject><subject>percutaneous ethanol ablation therapy</subject><subject>Rabbits</subject><subject>Scanners</subject><subject>Sectioning</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><subject>Ultrasound</subject><subject>vx2 liver cancer model</subject><issn>2253-5969</issn><issn>2253-5969</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks9rFDEYhgdRbKk9eZcBL4JMTSbJJLkIstS2smDRrXgyJJMv3SyZyZrMFPvfN3XX0nrKr4eHlzdfVb3G6KTFlH_4cr44-U4QRoI8qw7blpGGyU4-f7Q_qI5z3iCEcDkhLl5WB4RIxDvZHVa_rsKUdI7zaJuz2Vuw9SWkfp70CHHO9em01mMMzaXug5_0Hwj1Ig7GjwVcrSHp7W3tYqq_aWP8VP_42dZLfwOpXs1DTPlV9cLpkOF4vx5VV59PV4vzZvn17GLxadn0FLGpEQwxKqzEhFhmHUWOSsMwSES5M4YLQQgmumPYagRSQkFazDEntNUOODmqLnZeG_VGbZMfdLpVUXv19yKma6XT5PsAShhkMXSCWeCUGS6BAe-oA2EoldwV18edazubAWwPY2koPJE-fRn9Wl3HGyVQsaKuCN7tBSn-niFPavC5hxB2naqWYUlKekIL-vY_dBPnNJaqCtUWIZeUFOr9jupTzDmBewiDkbofA1XGQO3HoNBvHud_YP99OrkD16msUw</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Chen, Li</creator><creator>Liu, Zhi-Xing</creator><creator>Bi, Qiu-Chen</creator><creator>Zhao, Jun</creator><creator>Liang, Qing-Rong</creator><creator>Tang, Qun</creator><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210101</creationdate><title>Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors</title><author>Chen, Li ; Liu, Zhi-Xing ; Bi, Qiu-Chen ; Zhao, Jun ; Liang, Qing-Rong ; Tang, Qun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abdomen</topic><topic>Ablation</topic><topic>Apoptosis</topic><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Cell division</topic><topic>Cell proliferation</topic><topic>Chemotherapy</topic><topic>combined therapy</topic><topic>Correlation analysis</topic><topic>Cytotoxicity</topic><topic>Dehydration</topic><topic>Drug dosages</topic><topic>Ethanol</topic><topic>Iodine</topic><topic>Kruskal-Wallis test</topic><topic>Laboratory animals</topic><topic>Liver cancer</topic><topic>Necrosis</topic><topic>new indication</topic><topic>Original Research</topic><topic>Paclitaxel</topic><topic>Peat</topic><topic>percutaneous ethanol ablation therapy</topic><topic>Rabbits</topic><topic>Scanners</topic><topic>Sectioning</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><topic>Ultrasound</topic><topic>vx2 liver cancer model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Li</creatorcontrib><creatorcontrib>Liu, Zhi-Xing</creatorcontrib><creatorcontrib>Bi, Qiu-Chen</creatorcontrib><creatorcontrib>Zhao, Jun</creatorcontrib><creatorcontrib>Liang, Qing-Rong</creatorcontrib><creatorcontrib>Tang, Qun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of hepatocellular carcinoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Li</au><au>Liu, Zhi-Xing</au><au>Bi, Qiu-Chen</au><au>Zhao, Jun</au><au>Liang, Qing-Rong</au><au>Tang, Qun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors</atitle><jtitle>Journal of hepatocellular carcinoma</jtitle><addtitle>J Hepatocell Carcinoma</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>8</volume><spage>263</spage><epage>270</epage><pages>263-270</pages><issn>2253-5969</issn><eissn>2253-5969</eissn><abstract>It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy (PEPCT) of VX2 carcinoma, a rabbit liver cancer model. A six-arm study was designed to quantify the correlation between paclitaxel (PTX) dose and tumor necrosis or cell proliferation, including sham group (2 mL saline, n=6), incremented dose of PTX (0, 12.5, 25, 37.5 mg) in 2.0 mL ethanol (n=6) and a conventional PEAT group (n=6) as comparison. The test was followed by contrast-enhanced ultrasonic (CEUS) before 7-day sacrifice, tumor harvest, and sectioning. Tumor necrosis ratio was radiologically and histologically quantified; modified proliferation index ( -PI) was proposed to quantify the PTX's pharmacological effects. A linear regression model was set to correlate the PTX dose with tumor necrosis ratio or cell proliferation index. The difference of radiological, histological necrosis ratio (HNR) and modified PI in six groups was analyzed via Kruskal-Wallis -test, Welch analysis of variance and one-way ANOVA. Incremental increases of PTX (0, 12.5, 25, 37.5 mg) correlated with greater fraction of tumor necrosis (R = 0.946, P&lt;0.001 for radiological necrosis ratio [RNR], R = 0.843, P&lt;0.001 forHNR), indicating that one week after procedure PTX's anti-proliferation and ethanol's dehydration co-induced severe tumor necrosis. Correlation analysis further testified a significant association between PTX dose and -PI (R = 0.860, P&lt;0.001). These results suggest a clear role for PTX-induced cytotoxicity and support the use of chemotherapeutic drugs in ablation therapy.</abstract><cop>New Zealand</cop><pub>Taylor &amp; Francis Ltd</pub><pmid>33907696</pmid><doi>10.2147/JHC.S301083</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2253-5969
ispartof Journal of hepatocellular carcinoma, 2021-01, Vol.8, p.263-270
issn 2253-5969
2253-5969
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8b0d1e685de745b79e5e764fe8b4497f
source Publicly Available Content Database; Taylor & Francis Open Access Journals; PubMed Central
subjects Abdomen
Ablation
Apoptosis
Biopsy
Cancer therapies
Cell division
Cell proliferation
Chemotherapy
combined therapy
Correlation analysis
Cytotoxicity
Dehydration
Drug dosages
Ethanol
Iodine
Kruskal-Wallis test
Laboratory animals
Liver cancer
Necrosis
new indication
Original Research
Paclitaxel
Peat
percutaneous ethanol ablation therapy
Rabbits
Scanners
Sectioning
Tumors
Ultrasonic imaging
Ultrasound
vx2 liver cancer model
title Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A11%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ultrasound-Guided%20Percutaneous%20Ethanol-Paclitaxel%20Combined%20Therapy%20for%20Rabbit%20VX2%20Liver%20Tumors&rft.jtitle=Journal%20of%20hepatocellular%20carcinoma&rft.au=Chen,%20Li&rft.date=2021-01-01&rft.volume=8&rft.spage=263&rft.epage=270&rft.pages=263-270&rft.issn=2253-5969&rft.eissn=2253-5969&rft_id=info:doi/10.2147/JHC.S301083&rft_dat=%3Cproquest_doaj_%3E2528067943%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-850548d9133d5df40f49b51e9047fbb7883313a651da0e99ef4021717342afe73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2528067943&rft_id=info:pmid/33907696&rfr_iscdi=true